

Summary Table: Heart Failure & Related Conditions

Category	Key Details
Pharmacologic Treatments	<ul style="list-style-type: none"> * Beta blockers, ACE inhibitors, & ARBs target neurohormonal pathways * Neprilysin inhibitors ↑ natriuretic peptides (ANP, BNP) * Combination therapy with ARBs prevents angiotensin II buildup
Natriuretic Peptides Mechanism	<ul style="list-style-type: none"> * ANP & BNP released in response to increased atrial & ventricular pressure * Promote vasodilation & diuresis by increasing Na & water excretion * Neprilysin inhibition ↑ peptide levels but must be combined with ARBs
Cardiac Amyloidosis	<ul style="list-style-type: none"> * Presents with dyspnea, wt gain, edema * <u>Restrictive</u> cardiomyopathy due to <u>extracellular</u> amyloid protein deposits * Ventricular thickening leads to diastolic dysfunction * Diagnosed via biopsy (pink amorphous deposits) & echocardiogram
Renin-Angiotensin System in HF	<ul style="list-style-type: none"> * Reduced cardiac output lowers renal perfusion, triggering renin release * Angiotensin II causes vasoconstriction, increasing afterload * Aldosterone leads to Na retention, worsening fluid overload
Asymptomatic LV Dysfunction	<ul style="list-style-type: none"> * ↓ ejection fraction (<50%) without symptoms * Sympathetic activation & RAAS compensate initially * Leads to increased norepinephrine, vasoconstriction, & heart rate * Eventually causes maladaptive remodeling & HF progression
Pulmonary Congestion in HF	<ul style="list-style-type: none"> * Elevated LVEDP transmits to lungs * Causes pulmonary edema, alveolar hemorrhage * Hemosiderin-laden macrophages (heart failure cells) found in alveoli
Heart Failure Medications	<ul style="list-style-type: none"> * Mortality-reducing drugs: Beta blockers, ACE inhibitors, ARBs, aldosterone antagonists, neprilysin inhibitors, SGLT2 inhibitors * Symptom management drugs: Loop diuretics, thiazide diuretics, digoxin * Contraindicated drugs: Non-dihydropyridine calcium channel blockers
Acute Decompensated HF	<ul style="list-style-type: none"> * Sxs include fatigue, dyspnea, orthopnea, lower extremity edema * Hemodynamic effects: ↑ LV end-diastolic pressure, pulmonary congestion * Can be caused by anthracycline chemotherapy (doxorubicin)
High-Output Heart Failure	<ul style="list-style-type: none"> * Caused by arteriovenous fistula, decreasing systemic vascular resistance * Leads to increased stroke volume, venous return, & cardiac output

Category	Key Details
	* Ultimately results in LV overload & HF
Sodium Nitroprusside in HF	* Used for hypertensive emergency & acute heart failure * Causes balanced vasodilation (↓ preload & afterload) * Maintains stroke volume & cardiac output
Restrictive Cardiomyopathy vs Dilated Cardiomyopathy	* Restrictive: Normal LV size, reduced compliance, pulmonary congestion * Dilated: Enlarged LV, reduced contractility, systolic dysfunction
Secondary Mitral Regurgitation in HF	* LV dilation leads to mitral annulus widening, causing regurgitation * Diuretics & vasodilators ↓ preload & LV dilation
Neurohormonal Compensation in HF	* Sympathetic activation: ↑ heart rate & contractility * RAAS activation: Raises afterload & fluid retention * Natriuretic peptides: Promote <i>vasodilation & diuresis</i> but are overpowered by RAAS
Acute Decompensated HF on X-Ray	* Findings include cardiomegaly, Kerley B lines, pleural effusion, pulmonary edema * Different from ARDS, COPD, pulmonary HTN
Heart Failure & Pulmonary Congestion	* Pulmonary congestion leads to hemosiderin-laden macrophages * Identified with Prussian blue stain